Ribo Newsroom

Ribo Proposes Share Swap to Acquire a Minority Stake of its Overseas Subsidiary, Advancing Global Integration Strategy

Ribo’s overseas R&D team and investors visited its Kunshan headquarters and Beijing R&D center for in-depth discussions on project advancement and cross-regional collaboration, strengthening R&D collaboration between the Chinese and Swedish teams and jointly advancing the global development of siRNA therapeutics.

Ribo announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications.

Ribo Launches Automated Intelligent Drug Screening Center to Advance siRNA+AI Drug Discovery

Ribo Officially Integrated into Stock Connect Southbound Trading Link, Embarking on a New Chapter in Capital Markets

Ribo Presented New Data Highlighting Triglycerides, ApoC3 and Cardiovascular Health at ESC 2026